956100-63-3 Usage
General Description
8-Bromo-2-chloroquinazoline is a chemical compound with the molecular formula C8H5BrClN3. It is a heterocyclic compound containing both bromine and chlorine atoms, as well as a quinazoline ring structure. 8-BROMO-2-CHLOROQUINAZOLINE has potential applications in pharmaceutical and chemical research, due to its unique structure and reactivity. It can be used as a building block in the synthesis of biologically active compounds, or as a starting material for the development of new medications. Additionally, 8-Bromo-2-chloroquinazoline may also have uses in the development of agrochemicals, dyes, and other industrial products. Its properties make it an interesting and valuable chemical for further exploration and development.
Check Digit Verification of cas no
The CAS Registry Mumber 956100-63-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,5,6,1,0 and 0 respectively; the second part has 2 digits, 6 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 956100-63:
(8*9)+(7*5)+(6*6)+(5*1)+(4*0)+(3*0)+(2*6)+(1*3)=163
163 % 10 = 3
So 956100-63-3 is a valid CAS Registry Number.
InChI:InChI=1/C8H4BrClN2/c9-6-3-1-2-5-4-11-8(10)12-7(5)6/h1-4H
956100-63-3Relevant articles and documents
CONDENSED-RING PYRIMIDYLAMINO DERIVATIVE, PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND APPLICATIONS THEREOF
-
, (2018/03/25)
Disclosed are a condensed-ring pyrimidylamino derivative, a preparation method therefor, and an intermediate, a pharmaceutical composition and applications thereof. The method for preparing the condensed-ring pyrimidylamino derivative comprises: in a solvent, in the presence of a palladium-containing catalyst, allowing a compound represented by formula I-a and a compound represented by formula I-b' to have a coupling reaction, and then preparing a compound represented by formula I by means of a deprotection reaction. Also disclosed applications of the condensed-ring pyrimidylamino derivative in the preparation of drugs for preventing, relieving and/or treating tumors or diseases caused by an anaplastic lymphoma kinase. The condensed-ring pyrimidylamino derivative of the present invention has an obvious restraint effect on the anaplastic lymphoma kinase.
CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
-
, (2015/03/13)
Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.